UCPVax 1mg/2ml

DRUG2 trials

Sponsors

CHUR Of Besançon, Centre Hospitalier Regional Universitaire, Centre Hospitalier Regional Universitaire

Conditions

GlioblastomaPatients with locally advancedmetastatic or unresectable hepatocellular carcinoma

Phase 2

TERTIO : Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a proof of concept randomized phase II study

RecruitingCTIS2022-500643-20-00

CHUR Of Besançon, Centre Hospitalier Regional Universitairemetastatic or unresectable hepatocellular carcinoma, Patients with locally advanced

Start: 2022-09-27Target: 104Updated: 2025-11-13

MATVAC-1 : EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA

Not yet recruitingCTIS2024-514399-42-00

Centre Hospitalier Regional UniversitaireGlioblastoma

Target: 98Updated: 2025-11-12